Link Silicon Valley
The fastest way to connect to the people, companies and capital of Silicon Valley
Free 30 Day Trial Account
Sign Up | Log In
Search
ACQUIRED COMPANY
 
My Lists

Shaman Pharmaceutical  (Stock symbol: SHMN ) Acquired by CymaBay Therapeutics (2000  amount undisclosed )

213 E. Grand Avenue
South San Francisco, CA 94080
USA
(650)-952-7070
Website Company Summary Management Team
Management

CEO: John M. Jack (8/99)
Sales/Marketing: Mark Losh
Former Employees: Gary Fischer Michel Bergh
Board

Outside board: (May no longer be on the board) Adrian Bellamy (DFS CEO);  James J. Bochnowski (Delphi Ventures) Pierre R. Lamond (Sequoia Capital) Herbert McDade (Chemex Pharma);  G. Kirk Raab (Genentech CEO);  David Titus (Technology Funding)
Company

Business description: Shaman Pharmaceutical derives drugs likely to be active without side effects because they come from plants with a long history of folk use.
Partners include: Eli LillyMerck;  Inverni;  Ono Pharmaceuticals
Capital

Rounds: 5
Capital raised: 26.3M
Ownership: Acquired by CymaBay Therapeutics (2000  amount undisclosed )
Stock Symbol: SHMN
Corporate investors: Robertson StephensEli Lilly;  Travelers;  TVI

Last Tweets


 

Last Mentions


Overview
Record updated: Apr 1998
Sector: Biotech
Year Founded: 1989
Headcount: 76-100
Rounds: 5
Capital Raised: 26.3M
Ownership: Acquired by CymaBay Therapeutics (2000  amount undisclosed )
Stock Symbol: SHMN